Last reviewed · How we verify
THVD-201
THVD-201 is a therapeutic vaccine designed to stimulate immune responses against human papillomavirus (HPV) for the treatment of HPV-related cancers.
THVD-201 is a therapeutic vaccine designed to stimulate immune responses against human papillomavirus (HPV) for the treatment of HPV-related cancers. Used for HPV-positive cervical cancer, HPV-positive head and neck cancer.
At a glance
| Generic name | THVD-201 |
|---|---|
| Sponsor | SK Chemicals Co., Ltd. |
| Drug class | Therapeutic vaccine |
| Target | HPV antigens (E6/E7) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
THVD-201 is an immunotherapeutic vaccine that targets HPV antigens to activate the patient's immune system against HPV-infected cells. The vaccine is intended to generate cellular and humoral immune responses that can recognize and eliminate HPV-positive cancer cells, particularly in patients with established HPV-related malignancies.
Approved indications
- HPV-positive cervical cancer
- HPV-positive head and neck cancer
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Myalgia
Key clinical trials
- Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB (PHASE3)
- Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- THVD-201 CI brief — competitive landscape report
- THVD-201 updates RSS · CI watch RSS
- SK Chemicals Co., Ltd. portfolio CI